The latest biotech news

Prothena, Parkinsons Disease, neurons, neurological diseases

News and Trends 15 Sep 2022

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […]

September 15, 2022 - 3 minutesmins - By Jim Cornall

PBC clinical trials: Gannex doses first patient

News and Trends 15 Sep 2022

Tridek-One brings in €16M to develop auto-immune diseases candidates

Tridek-One SAS, a French biotech startup specialized in the research and development of CD31 agonists to restore immune balance, has closed a €16 million ($16.1 million) new financing round. The financing was led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures, as well as historical investors AdBio partners and […]

September 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Sep 2022

New company formed to boost life sciences in Singapore

ClavystBio, a company established by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek, has launched, with its mission to accelerate the commercialization of life sciences discoveries and innovation in Singapore. The life sciences sector is set to be a key driver of Singapore’s future economy. The sector currently employs 25,000 workers and contributes to […]

September 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Recursion adds FAP and C. diff clinical trials

Recursion Pharmaceuticals has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. The phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule […]

September 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering

Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

NTU Singapore opens microbiome research center to study obesity and chronic diseases

Nanyang Technological University, Singapore (NTU Singapore) has created the Centre for Microbiome Medicine – a research facility that aims to improve human health and find new ways to treat diseases by leveraging the microbiome, which are naturally present microorganisms that play a vital role in our wellbeing. The research centre at NTU Singapore’s Lee Kong […]

September 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Pancreatic cancer study using dual-cell therapy yields positive results

Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences

LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […]

September 14, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Sep 2022

SparingVision raises €75M for genomic medicines for ocular diseases

SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, has raised €75 million ($75 million) in series B financing. The round was co-led by Jeito Capital and UPMC Enterprises, with additional participation from 4BIO Capital, Bpifrance, the RD fund, venture arm of Foundation Fighting Blindness, and Ysios Capital. Proceeds from the financing will […]

September 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Collaboration to explore gene therapy products for neurodegenerative disorders

Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Sep 2022

New study reveals first genetic links in ME and chronic fatigue syndrome

For the first time in more than 30 years, replicable genetic findings have been reported in the study into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). UK-based PrecisionLife today (September 14) unveiled the results offering new approaches for better diagnosis and treatments of patients. The data has also been submitted for peer reviewed publication and is available […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Results of phase 3 trial of injection for ovarian cancer imaging published

An injection for intraoperative imaging of folate receptor positive ovarian cancer can identify more of the disease than is unable to be identified conventionally. Biotech company On Target Laboratories announced that the results from its phase 3, 006 study of the Cytalux (pafolacianine) injection had been published in the Journal of Clinical Oncology yesterday (September […]

September 13, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug

Tridek-One brings in €16M to develop auto-immune diseases candidates

New company formed to boost life sciences in Singapore

Recursion adds FAP and C. diff clinical trials

Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering

NTU Singapore opens microbiome research center to study obesity and chronic diseases

Pancreatic cancer study using dual-cell therapy yields positive results

Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences

SparingVision raises €75M for genomic medicines for ocular diseases

Collaboration to explore gene therapy products for neurodegenerative disorders

New study reveals first genetic links in ME and chronic fatigue syndrome

Results of phase 3 trial of injection for ovarian cancer imaging published

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!